Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the “Robert M. Nerem Lecture” at the 17 th Annual Hilton Head Workshop, "Regenerative Medicine: Technologies Enabling Novel Therapies" being held on Hilton Head Island, March 20-23. The goal of the workshop is to bring the community together in an intimate, "Gordon-conference style" forum to share the latest insights and discoveries in this rapidly progressing field. Dr. Lanza’s Lecture, entitled “The Use of Pluripotent Stem Cells in Regenerative Medicine,” will take place on Saturday, March 23, at 5:00p.m. EDT.
Dr. Lanza’s presentation is the second annual Nerem Lecture, with the first having been delivered last year by George Q. Daley, M.D., Ph.D. Samuel E. Lux IV Professor of Hematology/Oncology and Director of the Stem Cell Transplantation Program at Children’s Hospital Boston, and Professor at Harvard Medical School.
The conference brings together leading researchers in the field of regenerative medicine, along with other scientists, engineers, and clinicians, including speakers from Harvard University, Stanford, Cornell, Duke, UCLA, and the University of Pennsylvania, among others.
About Advanced Cell Technology, Inc.Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.